NasdaqCM - Nasdaq Real Time Price USD

Citius Oncology, Inc. (CTOR)

0.5540 +0.0245 (+4.63%)

At close: October 30 at 4:00:01 PM EDT

0.5536 -0.0004 (-0.07%)

After hours: October 30 at 5:35:12 PM EDT

Loading Chart for CTOR

Chart Range Bar

Interval:

In partnership with ChartIQ

Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026

Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption

$Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies$

Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies

U.S. markets open in 1h 53m

Citius Oncology, Inc. (CTOR)

Recent News

Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026

Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption

Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies

Citius raises $36.5m for Lymphir commercialisation

Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization

Citius Oncology Ships First International Order of LYMPHIR™ to Europe

Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development

Citius Oncology and Uniphar sign European distribution deal for Lymphir

Related Tickers